Scinai Immunotherapeutics Reports Q2 2024 Results

Ticker: SCNI · Form: 6-K · Filed: 2024-08-15T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, business-update, foreign-private-issuer

TL;DR

Scinai Immunotherapeutics dropped its Q2 2024 earnings report and business update on Aug 15.

AI Summary

On August 15, 2024, Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K to report its Q2 2024 financial results and provide a business update. The company, incorporated in Israel, is involved in biological products and is headquartered at Jerusalem BioPark.

Why It Matters

This filing provides investors with an update on Scinai Immunotherapeutics' financial performance and business progress for the second quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing and does not contain significant new risk factors.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K is to report the registrant's Q2 2024 financial results and provide a business update, as announced in a press release dated August 15, 2024.

What was Scinai Immunotherapeutics Ltd. formerly known as?

Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.

When did the company change its name?

The company's name change from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. occurred on June 24, 2014.

Where is Scinai Immunotherapeutics Ltd. located?

The company's principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.

Does Scinai Immunotherapeutics file annual reports under Form 20-F or 40-F?

Scinai Immunotherapeutics indicates that it files annual reports under Form 20-F.

From the Filing

0001213900-24-069347.txt : 20240815 0001213900-24-069347.hdr.sgml : 20240815 20240815073617 ACCESSION NUMBER: 0001213900-24-069347 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20240815 FILED AS OF DATE: 20240815 DATE AS OF CHANGE: 20240815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 241210636 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0211529-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On August 15, 2024, Scinai Immunotherapeutics Ltd. issued a press release announcing publishing of Q2 2024 financial results and providing a business update. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No. Description 99.1 Press release dated August 15, 2024. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 15, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2 EX-99.1 2 ea021152901ex99-1_scinai.htm PRESS RELEASE DATED AUGUST 15, 2024 Exhibit 99.1 Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 JERUSALEM, Aug. 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the quarter ended June 30, 2024 and provided a business update. The Company will hold a webinar covering its Q2 2024 financial results and business update on August 20 th at 11AM EDT/18:00 Israel time. Registration for the webinar can be done using the following LINK. Business Update & Recent Highlights Conversion of EIB Loan into Equity and Regaining Nasdaq Compliance On June 7, 2024, the Company announced that on June 5, 2024, it had received formal notification from the Listing Qualification Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company remains non-complian

View on Read The Filing